• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Ocugen Provides Business Update with First Quarter 2025 Financial Results

    5/9/25 8:01:07 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OCGN alert in real time by email

    Conference Call and Webcast Today at 8:30 a.m. ET

    • OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026

    • Anticipate initiating OCU410ST Phase 2/3 pivotal confirmatory clinical trial for Stargardt disease mid- 2025

    MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported first quarter 2025 financial results along with a general business update.

    "All three of our novel modifier gene therapies are advancing through the clinic and we are on track to meet our goal of three Biologics License Application (BLA)/Marketing Authorization Application (MAA) filings in the next three years," said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. "We remain steadfast in our mission to provide a one-time therapy for life to address considerable unmet medical needs that exist for millions of patients facing the terrifying prospect of losing their vison."

    In January, the Company announced positive two-year long-term safety and efficacy data from the Phase 1/2 clinical trial of OCU400 for RP that demonstrated a durable, clinically meaningful, and statistically significant (p=0.005) improvement in visual function (LLVA) in all evaluable treated subjects at two years when compared to untreated eyes. Additionally, 100% (10/10) of treated evaluable subjects demonstrated improvement or preservation in visual function compared to untreated eyes. This data further supports the gene-agnostic mechanism of action of OCU400, a broad RP treatment not restricted to specific mutations, with durability.

    The OCU400 Phase 3 liMeliGhT clinical trial is open to all eligible RP patients—early to advanced stage RP including pediatric subjects age 5+—regardless of gene mutation (syndromic and non-syndromic forms of RP). OCU400 has the potential to treat all 300,000 RP patients in the U.S. and EU.

    Alignment was reached with the FDA to move forward with a Phase 2/3 pivotal confirmatory trial for OCU410ST for Stargardt disease, which includes an adaptive design with a masked interim analysis at 8 months. Stargardt disease affects 100,000 people in the U.S. and EU. The Phase 2/3 clinical trial will randomize 51 subjects, 34 of whom will receive a single, subretinal, injection of OCU410ST (200 μL at a concentration of 1.5 × 10¹¹ vector genomes/mL) in the eye with worse visual acuity, and 17 of whom will serve as untreated controls. The primary endpoint in the clinical trial is change in atrophic lesion size. Key secondary endpoints include visual acuity as measured by best corrected visual acuity (BCVA) and LLVA compared to untreated controls. One-year data will be utilized for the BLA filing. The latest data from the OCU410ST Phase 1 clinical trial demonstrates atrophic lesions grew slower by 54% at six months in evaluable treated eyes when compared to untreated eyes. In BCVA, treated eyes demonstrated statistically significant (p=0.02) improvement in visual function when compared to untreated fellow eyes. Ocugen plans to initiate the Phase 2/3 study by mid-year with a target BLA filing in 2027.

    In February, dosing was complete in the Phase 2 portion of the OCU410 Phase 1/2 ArMaDa clinical trial for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD). In evaluable subjects, OCU410 12-month data demonstrates a 4-line (23-letter) gain in visual acuity and 41% slower GA lesion growth in treated eyes versus untreated fellow eyes after a single injection. The unique mechanism of action of OCU410 targets multiple pathways associated with dAMD pathogenesis, in contrast to products currently approved or under development that treat only one cause of GA, require multiple injections per year, and have safety considerations. Approximately 2-3 million patients in the U.S. & EU and 8 million globally suffer from GA.

    All of Ocugen's modifier gene therapies—OCU400 for RP, OCU410ST for Stargardt disease, and OCU410 for GA were granted Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency's (EMA) Committee for Advanced Therapies. ATMP classification is granted to medicines that can offer groundbreaking opportunities for the treatment of disease and accelerates the regulatory review timeline of this potential one-time gene therapy for life. Additionally, this classification allows the Company to interact with the EMA more frequently for scientific advice and protocol assistance.

    Relevant to Ocugen's recent ATMP classifications, Dr. Musunuri participated in a panel addressing the journey of successfully commercializing ATMPs, which focused on the challenges and strategies in achieving commercial success while also ensuring access for the patients who need them, during the 2025 Cell & Gene Meeting on the Mediterranean, hosted by the Alliance for Regenerative Medicine. The Meeting on the Med provided an excellent forum to reach a wide audience about the importance of changing the treatment paradigm by bringing potentially transformative modifier gene therapies to market.

    Also in the first quarter of 2025, the first patient was dosed in the Phase 1 clinical trial for OCU200, the Company's biologic product candidate for diabetic macular edema. Currently, patients are being dosed in the second cohort and Ocugen is planning to complete the Phase 1 clinical trial in the second half of this year. The Company intends to initiate the Phase 3 trial for NeoCart® contingent on adequate availability of funding and/or based on the potential of a future partnership. Finally, the Investigational New Drug application is in effect for OCU500, and the National Institute of Allergy and Infectious Diseases intends to initiate a Phase 1 clinical trial in the second quarter of 2025. Ocugen is continuing discussions with relevant government agencies as well as strategic partners regarding developmental funding for its vaccines technology for flu.

    "We have had a strong start to 2025 and are approaching considerable milestones in the next few months," said Dr. Musunuri. "I am enthusiastic about where we are as a Company, with a clear and precise business strategy to operate efficiently in service of our patients and shareholders."

    Modifier Gene Therapy Platform—a Novel First-in-Class Platform

    • OCU400 for RP – The EMA provided a positive opinion for ATMP classification for OCU400 and granted eligibility to submit the OCU400 MAA via the centralized procedure as an ATMP based on the current study design and statistical analysis plan. Actively recruiting patients in the U.S. and Canada in the Phase 3 liMeliGhT clinical trial and on track to meet BLA/MAA filing targets in mid-2026.

    • OCU410ST for Stargardt Disease – Received FDA alignment to move forward with Phase 2/3 pivotal confirmatory clinical trial, which can be the basis of a BLA submission. ATMP classification granted by the EMA.

    • OCU410 for GA – Announced that dosing was complete, ahead of schedule, in the Phase 2 portion of the Phase 1/2 ArMaDa clinical trial for OCU410. Received ATMP classification from the EMA.

    First Quarter 2025 Financial Results

    • The Company's cash and restricted cash totaled $38.1 million as of March 31, 2025, compared to $58.8 million as of December 31, 2024. The Company had 292.0 million shares of common stock outstanding as of March 31, 2025. The Company expects its cash and restricted cash runway into the first quarter of 2026.

    • Total operating expenses for the three months ended March 31, 2025 were $16.0 million and included research and development expenses of $9.5 million and general and administrative expenses of $6.5 million. This compares to total operating expenses for the three months ended March 31, 2024 of $13.2 million that included research and development expenses of $6.8 million and general and administrative expenses of $6.4 million.
    • Ocugen reported a $0.05 net loss per common share for the three months ended March 31, 2025 compared to a $0.05 net loss per common share for the three months ended March 31, 2024.

    Conference Call and Webcast Details

    Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent business highlights. Ocugen's senior management team will host the call, which will be open to all listeners. There will also be a question-and-answer session following the prepared remarks.

    Attendees are invited to participate on the call or webcast using the following details:

    Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers

    Conference ID: 1773288

    Webcast: Available on the events section of the Ocugen investor site

    A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugen investor site.

    About Ocugen, Inc.

    Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen's modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us X and LinkedIn.

    Cautionary Note on Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, strategy, business plans and objectives for Ocugen's clinical programs, plans and timelines for the preclinical and clinical development of Ocugen's product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, the ability to initiate new clinical programs; Ocugen's expected cash runway, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our annual and periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.



    Contact:

    Tiffany Hamilton

    Head of Communications

    [email protected] 

    (Tables to follow)

    OCUGEN, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands)

    (Unaudited)
        
     March 31, 2025 December 31, 2024
    Assets   
    Current assets   
    Cash$37,800  $58,514 
    Prepaid expenses and other current assets 6,164   3,168 
    Total current assets 43,964   61,682 
    Property and equipment, net 15,989   16,554 
    Restricted cash 309   307 
    Other assets 4,198   3,899 
    Total assets$64,460  $82,442 
    Liabilities and stockholders' equity   
    Current liabilities   
    Accounts payable$3,224  $4,243 
    Accrued expenses and other current liabilities 12,926   15,500 
    Operating lease obligations 736   519 
    Current portion of long-term debt —   1,326 
    Total current liabilities 16,886   21,588 
    Non-current liabilities   
    Operating lease obligations, less current portion 3,418   3,313 
    Long term debt, net 27,669   27,345 
    Other non-current liabilities 573   564 
    Total non-current liabilities 31,660   31,222 
    Total liabilities 48,546   52,810 
        
    Stockholders' equity   
    Common stock 2,922   2,915 
    Treasury stock (48)  (48)
    Additional paid-in capital 368,571   366,938 
    Accumulated other comprehensive income 40   48 
    Accumulated deficit (355,571)  (340,221)
    Total stockholders' equity 15,914   29,632 
    Total liabilities and stockholders' equity$64,460  $82,442 
            



    OCUGEN, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (in thousands, except share and per share amounts)

    (Unaudited)
     
     Three months ended March 31,
      2025   2024 
    Collaborative arrangement revenue$1,481  $1,014 
    Total revenue 1,481   1,014 
    Operating expenses   
    Research and development 9,529   6,826 
    General and administrative 6,453   6,404 
    Total operating expenses 15,982   13,230 
    Loss from operations (14,501)  (12,216)
    Interest (expense) income, net (914)  302 
    Other income (expense), net 65   (10)
    Net loss$(15,350) $(11,924)
    Other comprehensive income (loss)   
    Foreign currency translation adjustment (8)  5 
    Comprehensive loss$(15,358) $(11,919)
        
    Net loss attributable to common shareholders— basic and diluted (15,350)  (11,899)
    Weighted shares used in calculating net loss per common share — basic and diluted 291,996,562   257,232,636 
    Net loss per share attributable to common shareholders — basic and diluted$(0.05) $(0.05)
        
    Net loss attributable to Series B Convertible Preferred shareholders — basic and diluted —   (25)
    Weighted shares used in calculating net loss per Series B Convertible Preferred Stock — basic and diluted —   54,745 
    Net loss per share attributable to Series B Convertible Preferred shareholders — basic and diluted$—  $(0.46)
            


    Primary Logo

    Get the next $OCGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OCGN

    DatePrice TargetRatingAnalyst
    10/15/2024$4.00Buy
    Maxim Group
    3/1/2023$3.50Neutral → Buy
    Chardan Capital Markets
    8/23/2022$5.00Buy
    Mizuho
    6/15/2022$8.00Buy
    ROTH Capital
    6/2/2022$4.50Overweight
    Cantor Fitzgerald
    2/28/2022$10.00 → $8.00Buy
    HC Wainwright & Co.
    7/26/2021Outperform
    Noble Capital Markets
    More analyst ratings

    $OCGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fernandes Prabhavathi bought $9,095 worth of shares (10,000 units at $0.91) (SEC Form 4)

      4 - Ocugen, Inc. (0001372299) (Issuer)

      12/2/24 4:15:25 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Castillo Kirsten bought $22,848 worth of shares (25,000 units at $0.91), increasing direct ownership by 50% to 75,000 units (SEC Form 4)

      4 - Ocugen, Inc. (0001372299) (Issuer)

      11/26/24 4:50:10 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ocugen Provides Business Update with First Quarter 2025 Financial Results

      Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026Anticipate initiating OCU410ST Phase 2/3 pivotal confirmatory clinical trial for Stargardt disease mid- 2025 MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported first quarter 2025 financial results along with a general business update. "All three of our novel modifier gene therapies are advancing through the clinic and we are on track to meet our goal of three Biologic

      5/9/25 8:01:07 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

      MALVERN, Pa., May 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, May 9, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 1773288Webcast: Available on the events section of the Ocuge

      5/2/25 8:00:37 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

      MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410ST for the treatment of Stargardt disease (Phase 2/3 pivotal confirmatory clinical trial), and OCU410 for the treatment of geographic atrophy (Phase 2 ArMaDa clinical trial), at The Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting at the Calvin L. Rampton Salt Palace Convention Center in Salt

      4/29/25 7:30:40 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

      SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

      11/12/24 4:59:47 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

      SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

      11/4/24 1:43:41 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Ocugen Inc.

      SC 13G - Ocugen, Inc. (0001372299) (Subject)

      10/16/24 12:41:30 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    SEC Filings

    See more
    • Ocugen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ocugen, Inc. (0001372299) (Filer)

      5/9/25 9:45:30 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Ocugen Inc.

      10-Q - Ocugen, Inc. (0001372299) (Filer)

      5/9/25 9:43:21 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Ocugen, Inc. (0001372299) (Filer)

      5/1/25 9:22:51 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    Financials

    Live finance-specific insights

    See more
    • Ocugen Provides Business Update with First Quarter 2025 Financial Results

      Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026Anticipate initiating OCU410ST Phase 2/3 pivotal confirmatory clinical trial for Stargardt disease mid- 2025 MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported first quarter 2025 financial results along with a general business update. "All three of our novel modifier gene therapies are advancing through the clinic and we are on track to meet our goal of three Biologic

      5/9/25 8:01:07 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

      MALVERN, Pa., May 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, May 9, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 1773288Webcast: Available on the events section of the Ocuge

      5/2/25 8:00:37 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

      Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three yearsCompleted dosing in OCU410 Phase 2 ArMaDa clinical trial (N=51) for geographic atrophy (GA). Data and Safety Monitoring Board (DSMB) recently reviewed interim safety data from Phase 2. All subjects from multiple dose levels in Phase 2 to date demonstrated a very favorable safety and tolerability profile.Positive 2-year long-term data across multiple mutations of retinitis pigmentosa (RP) from the Phase 1/2 clinical trial of OCU400 demonstrated a durable and statistically significant (p=0.005) improvement in visual f

      3/5/25 7:02:00 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Ocugen with a new price target

      Maxim Group initiated coverage of Ocugen with a rating of Buy and set a new price target of $4.00

      10/15/24 8:07:55 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen upgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets upgraded Ocugen from Neutral to Buy and set a new price target of $3.50

      3/1/23 9:04:17 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mizuho initiated coverage on Ocugen with a new price target

      Mizuho initiated coverage of Ocugen with a rating of Buy and set a new price target of $5.00

      8/23/22 7:19:06 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Accounting Officer Ramachandran Ramesh

      4 - Ocugen, Inc. (0001372299) (Issuer)

      1/6/25 5:02:56 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Upadhyay Arun covered exercise/tax liability with 41,633 shares, decreasing direct ownership by 12% to 306,197 units (SEC Form 4)

      4 - Ocugen, Inc. (0001372299) (Issuer)

      1/6/25 5:02:25 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Musunuri Shankar covered exercise/tax liability with 177,146 shares, decreasing direct ownership by 9% to 1,832,723 units (SEC Form 4)

      4 - Ocugen, Inc. (0001372299) (Issuer)

      1/6/25 5:01:44 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OCGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

      MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen, will speak during the workshop titled, "U.S.-India Biotechnology Cooperation: Realizing Benefits, Reducing Risks." This two-day event will take place from September 9-11, 2024 in New Delhi, India. "It is an honor to join the impressive group of thought leaders in this groundbreaking forum," said Dr. Musunuri. "There are endless opportunities to leverage the bes

      9/9/24 6:30:12 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

      MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. "Inclusion of Ocugen to the Russell 3000® Index is our latest milestone, adding to what has already been a transformational year for the Company with three of our game-changing modifier gene therapies targeting

      5/28/24 7:02:39 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; June 10, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN) investors that a lawsuit was filed on behalf of investors that purchased Ocugen securities. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. On April 1, 2024, Ocugen filed a Cur

      5/13/24 7:44:39 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care